Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Non-Current Assets: 2023-2025

Historic Non-Current Assets for Compass Therapeutics (CMPX) over the last 3 years, with Sep 2025 value amounting to $10.1 million.

  • Compass Therapeutics' Non-Current Assets rose 26.56% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 26.56%. This contributed to the annual value of $7.7 million for FY2024, which is 155.58% up from last year.
  • Latest data reveals that Compass Therapeutics reported Non-Current Assets of $10.1 million as of Q3 2025, which was down 3.47% from $10.5 million recorded in Q2 2025.
  • Over the past 5 years, Compass Therapeutics' Non-Current Assets peaked at $10.5 million during Q2 2025, and registered a low of $2.1 million during Q2 2024.
  • For the 3-year period, Compass Therapeutics' Non-Current Assets averaged around $5.7 million, with its median value being $4.4 million (2023).
  • In the last 5 years, Compass Therapeutics' Non-Current Assets plummeted by 47.17% in 2024 and then spiked by 408.62% in 2025.
  • Over the past 3 years, Compass Therapeutics' Non-Current Assets (Quarterly) stood at $3.0 million in 2023, then skyrocketed by 155.58% to $7.7 million in 2024, then climbed by 26.56% to $10.1 million in 2025.
  • Its Non-Current Assets was $10.1 million in Q3 2025, compared to $10.5 million in Q2 2025 and $7.3 million in Q1 2025.